UroGen Pharma (URGN) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $72.5 million versus the consensus estimate of $62.16 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
- Jefferies Upgrades Inovio Pharmaceuticals (INO) to Buy
- Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
